186 related articles for article (PubMed ID: 30367145)
61. A Gelatinases-targeting scFv-based Fusion Protein Shows Enhanced Antitumour Activity with Endostar against Hepatoma.
Gao R; Li L; Shang B; Zhao C; Sheng W; Li D
Basic Clin Pharmacol Toxicol; 2015 Aug; 117(2):105-16. PubMed ID: 25615234
[TBL] [Abstract][Full Text] [Related]
62. Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.
Kudo K; Ohashi K; Makimoto G; Higo H; Kato Y; Kayatani H; Kurata Y; Takami Y; Minami D; Ninomiya T; Kubo T; Ichihara E; Sato A; Hotta K; Yoshino T; Tanimoto M; Kiura K
Mol Oncol; 2017 Jun; 11(6):670-681. PubMed ID: 28388009
[TBL] [Abstract][Full Text] [Related]
63. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
von Pawel J; Spigel DR; Ervin T; Losonczy G; Barlesi F; Juhász E; Anderson M; McCall B; Wakshull E; Hegde P; Ye W; Chen D; Chang I; Rhee I; Reck M
Oncologist; 2018 Jun; 23(6):654-e58. PubMed ID: 29438092
[TBL] [Abstract][Full Text] [Related]
64. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis.
Yang K; Wang YJ; Chen XR; Chen HN
Clin Drug Investig; 2010; 30(4):229-41. PubMed ID: 20225906
[TBL] [Abstract][Full Text] [Related]
65. Endostar, a Modified Endostatin Induces Vascular Normalization to Improve Chemotherapy Efficacy Through Suppression of Src Signaling Pathway.
Yu M; Han Y; Zhuo H; Zhang S
Cancer Biother Radiopharm; 2018 May; 33(4):131-138. PubMed ID: 29694242
[TBL] [Abstract][Full Text] [Related]
66. Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care.
Patel JD; Paz-Ares L; Zinner RG; Barlesi F; Koustenis AG; Obasaju CK
Clin Lung Cancer; 2018 Nov; 19(6):e823-e830. PubMed ID: 30369427
[TBL] [Abstract][Full Text] [Related]
67. Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells.
Gao H; Xue J; Zhou L; Lan J; He J; Na F; Yang L; Deng L; Lu Y
Cancer Lett; 2015 Aug; 365(1):79-88. PubMed ID: 25982206
[TBL] [Abstract][Full Text] [Related]
68. Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer.
Stevenson JP; Langer CJ; Somer RA; Evans TL; Rajagopalan K; Krieger K; Jacobs-Small M; Dyanick N; Milcarek B; Coakley S; Walker S; Eaby-Sandy B; Hageboutros A
Cancer; 2012 Nov; 118(22):5580-7. PubMed ID: 22544579
[TBL] [Abstract][Full Text] [Related]
69. Study on the clinical effects of targeted therapy on elderly patients with gastric cancer.
Gao L; Li W; Liu Y; Zhang C; Gao W; Wang L
Pak J Pharm Sci; 2021 Sep; 34(5(Special)):2041-2045. PubMed ID: 34862871
[TBL] [Abstract][Full Text] [Related]
70. Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model.
Maj E; Filip-Psurska B; Milczarek M; Psurski M; Kutner A; Wietrzyk J
Int J Oncol; 2018 Feb; 52(2):337-366. PubMed ID: 29345296
[TBL] [Abstract][Full Text] [Related]
71. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
[TBL] [Abstract][Full Text] [Related]
72. Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma.
Zhou N; Liu C; Hou H; Zhang C; Liu D; Wang G; Liu K; Zhu J; Lv H; Li T; Zhang X
Oncotarget; 2016 Nov; 7(44):72373-72379. PubMed ID: 27738308
[TBL] [Abstract][Full Text] [Related]
73. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions.
Ellis PM; Al-Saleh K
Crit Rev Oncol Hematol; 2012 Oct; 84(1):47-58. PubMed ID: 22405734
[TBL] [Abstract][Full Text] [Related]
74. Current treatments for advanced stage non-small cell lung cancer.
Stinchcombe TE; Socinski MA
Proc Am Thorac Soc; 2009 Apr; 6(2):233-41. PubMed ID: 19349493
[TBL] [Abstract][Full Text] [Related]
75. Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma.
Chen N; Ren M; Li R; Deng X; Li Y; Yan K; Xiao L; Yang Y; Wang L; Luo M; Fay WP; Wu J
Mol Cancer; 2015 Jul; 14():140. PubMed ID: 26215730
[TBL] [Abstract][Full Text] [Related]
76. Sorafenib for lung cancer: is the "Battle" still open?
Bria E; Pilotto S; Tortora G
Expert Opin Investig Drugs; 2012 Oct; 21(10):1445-8. PubMed ID: 22799503
[TBL] [Abstract][Full Text] [Related]
77. Bevacizumab in non small cell lung cancer.
Sandler A
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4613-6. PubMed ID: 17671151
[TBL] [Abstract][Full Text] [Related]
78. Analysis of cardio-cerebrovascular adverse events in patients with brain metastasis from lung cancer treated with antiangiogenic drugs.
Zhang Y; Zhang H; Song W
Pak J Pharm Sci; 2022 Jan; 35(1):77-84. PubMed ID: 35221276
[TBL] [Abstract][Full Text] [Related]
79. The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC.
Zhou L; Zhang W; Xiang Y; Qian Z; Zhou J; Ni L; Feng Y; Gao B
Open Life Sci; 2023; 18(1):20220533. PubMed ID: 36910471
[TBL] [Abstract][Full Text] [Related]
80. Simultaneous Administration of Bevacizumab with Bee-Pollen Extract-Loaded Hybrid Protein Hydrogel NPs Is a Promising Targeted Strategy against Cancer Cells.
Hanafy NAN; Eltonouby EAB; Salim EI; Mahfouz ME; Leporatti S; Hafez EH
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
